TLC-2716
Severe Hypertriglyceridemia and Metabolic Liver Disease
Phase 2aActive
Key Facts
Indication
Severe Hypertriglyceridemia and Metabolic Liver Disease
Phase
Phase 2a
Status
Active
Company
About OrsoBio
OrsoBio is a private, clinical-stage biotech focused on novel small molecule therapies for severe metabolic diseases, aiming to restore energy homeostasis. Its pipeline includes programs like TLC-2716, an LXR inverse agonist in Phase 2a for hypertriglyceridemia and metabolic liver disease, and TLC-1180, a protonophore being explored for obesity. The company is backed by a seasoned leadership team and notable venture capital firms, having raised significant funding, including a $67M round in 2024.
View full company profile